Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor

Tools

Item Type:	Article
Title:	Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor
Creators Name:	Rauch, A., Seitz, S., Baschant, U., Schilling, A.F., Illing, A., Stride, B., Kirilov, M., Mandic, V., Takacz, A., Schmidt-Ullrich, R., Ostermay, S., Schinke, T., Spanbroek, R., Zaiss, M.M., Angel, P.E., Lerner, U.H., David, J.P., Reichardt, H.M., Amling, M., Schuetz, G. and Tuckermann, J.P.
Abstract:	Development of osteoporosis severely complicates long-term glucocorticoid (GC) therapy. Using a Cre-transgenic mouse line, we now demonstrate that GCs are unable to repress bone formation in the absence of glucocorticoid receptor (GR) expression in osteoblasts as they become refractory to hormone-induced apoptosis, inhibition of proliferation, and differentiation. In contrast, GC treatment still reduces bone formation in mice carrying a mutation that only disrupts GR dimerization, resulting in bone loss in vivo, enhanced apoptosis, and suppressed differentiation in vitro. The inhibitory GC effects on osteoblasts can be explained by a mechanism involving suppression of cytokines, such as interleukin 11, via interaction of the monomeric GR with AP-1, but not NF-kappaB. Thus, GCs inhibit cytokines independent of GR dimerization and thereby attenuate osteoblast differentiation, which accounts, in part, for bone loss during GC therapy.
Keywords:	Apoptosis, Cell Differentiation, Dimerization, Glucocorticoids, Interleukin-11, Osteoblasts, Osteogenesis, Glucocorticoid Receptors, Transcription Factor AP-1, Animals, Mice
Source:	Cell Metabolism
ISSN:	1550-4131
Publisher:	Cell Press
Volume:	11
Number:	6
Page Range:	517-531
Date:	9 June 2010
Official Publication:	https://doi.org/10.1016/j.cmet.2010.05.005
PubMed:	View item in PubMed

Repository Staff Only: item control page